EVERETT HISTORICAL / SHUTTERSTOCK.COM
Nearly three years after the introduction of the inter partes review, LSIPR explores its impact on the life sciences sector and asks whether it is creating a culture of ‘reverse trolling’.
Sometimes, a good tool can find itself in the wrong hands.
In September 2012, the America Invents Act (AIA) introduced the inter partes review (IPR), a quicker, more cost-effective way of challenging patents on the basis of prior art consisting of patents or printed publications.
The AIA patent reform was squarely aimed at curbing the activities of non-practising entities (NPEs), also known as ‘patent trolls’, which had made life unpredictable for innovators in the tech industry.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
inter-partes review, AIA, NPEs, IPR, US Court of Appeals for the Federal Circuit, patent troll,